Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGINTRON for HIV-1 Residual Viremia
NCT01295515Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- May 2017
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in human immunodeficiency virus infection (HIV), sponsored by National Cancer Institute. Primary endpoints: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at 4 weeks and Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Deoxyribonucleic Acid (DNA) at 4 weeks. Started Feb 2011; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01295515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295515.